ACRS
Aclaris Therapeutics, Inc.
Medical - Diagnostics & Research
Market Cap$586M
5Y Perf.+244.7%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
ACRS vs DBVT
Revenue, margins, valuation, and 5-year total return — side by side.
DBVT
DBV Technologies S.A.
Biotechnology
Market Cap$1712.35T
5Y Perf.-58.8%
ACRS vs DBVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ACRS | DBVT |
|---|---|---|
| Industry | Medical - Diagnostics & Research | Biotechnology |
| Market Cap | $586M | $1712.35T |
| Revenue (TTM) | $8M | $0.00 |
| Net Income (TTM) | $-65M | $-168M |
| Gross Margin | 73.3% | — |
| Operating Margin | -9.8% | — |
| Total Debt | $0.00 | $22M |
| Cash & Equiv. | $20M | $194M |
ACRS vs DBVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ACRS
DBVT
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Aclaris Therapeutic… (ACRS) | 100 | 344.7 | +244.7% |
| DBV Technologies S.… (DBVT) | 100 | 41.2 | -58.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ACRS vs DBVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ACRS leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. DBV Technologies S.A. is the stronger pick specifically for profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
ACRS
Aclaris Therapeutics, Inc.
The Income Pick
ACRS carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.30
- Rev growth -58.2%, EPS growth 69.0%, 3Y rev CAGR -35.9%
- -76.3% 10Y total return vs DBVT's -87.0%
Best for: income & stability and growth exposure
DBVT
DBV Technologies S.A.
The Quality Compounder
DBVT is the clearest fit if your priority is quality.
- 0.3% margin vs ACRS's -8.3%
Best for: quality
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ACRS | -58.2% revenue growth vs DBVT's -100.0% |
| Quality / Margins | DBVT | 0.3% margin vs ACRS's -8.3% |
| Stability / Safety | ACRS | Beta 0.30 vs DBVT's 1.26 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | ACRS | +288.8% vs DBVT's +110.4% |
| Efficiency (ROA) | ACRS | -40.5% ROA vs DBVT's -89.0% |
ACRS vs DBVT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
Segment breakdown not available.
ACRS vs DBVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLACRSLAGGINGDBVT
DBVTDBV Technologies S.A.
1leads
ACRSAclaris Therapeutics,…
2leads
6 Total Categories
CATEGORYLEADERvs DBVTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
DBVT1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ACRS4/6
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
ACRS2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
DBVT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
ACRS and DBVT operate at a comparable scale, with $8M and $0 in trailing revenue.
| Metric | ACRSAclaris Therapeut… | DBVTDBV Technologies … |
|---|---|---|
| RevenueTrailing 12 months | $8M | $0 |
| EBITDAEarnings before interest/tax | -$76M | -$112M |
| Net IncomeAfter-tax profit | -$65M | -$168M |
| Free Cash FlowCash after capex | -$47M | -$151M |
| Gross MarginGross profit ÷ Revenue | +73.3% | — |
| Operating MarginEBIT ÷ Revenue | -9.8% | — |
| Net MarginNet income ÷ Revenue | -8.3% | — |
| FCF MarginFCF ÷ Revenue | -6.0% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -85.9% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +84.2% | +91.5% |
DBVT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — ACRS and DBVT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | ACRSAclaris Therapeut… | DBVTDBV Technologies … |
|---|---|---|
| Market CapShares × price | $586M | $1712.35T |
| Enterprise ValueMkt cap + debt − cash | $566M | $1712.35T |
| Trailing P/EPrice ÷ TTM EPS | -9.17x | -0.76x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 74.83x | — |
| Price / BookPrice ÷ Book value/share | 5.78x | 0.66x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — ACRS and DBVT each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
ACRS leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
ACRS delivers a -63.0% return on equity — every $100 of shareholder capital generates $-63 in annual profit, vs $-130 for DBVT. On the Piotroski fundamental quality scale (0–9), DBVT scores 4/9 vs ACRS's 3/9, reflecting mixed financial health.
| Metric | ACRSAclaris Therapeut… | DBVTDBV Technologies … |
|---|---|---|
| ROE (TTM)Return on equity | -63.0% | -130.2% |
| ROA (TTM)Return on assets | -40.5% | -89.0% |
| ROICReturn on invested capital | -53.5% | — |
| ROCEReturn on capital employed | -47.7% | -145.7% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 |
| Debt / EquityFinancial leverage | — | 0.13x |
| Net DebtTotal debt minus cash | -$20M | -$172M |
| Cash & Equiv.Liquid assets | $20M | $194M |
| Total DebtShort + long-term debt | $0 | $22M |
| Interest CoverageEBIT ÷ Interest expense | — | -189.82x |
ACRS leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — ACRS and DBVT each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in DBVT five years ago would be worth $3,090 today (with dividends reinvested), compared to $2,118 for ACRS. Over the past 12 months, ACRS leads with a +288.8% total return vs DBVT's +110.4%. The 3-year compound annual growth rate (CAGR) favors DBVT at 6.2% vs ACRS's -16.7% — a key indicator of consistent wealth creation.
| Metric | ACRSAclaris Therapeut… | DBVTDBV Technologies … |
|---|---|---|
| YTD ReturnYear-to-date | +68.8% | +4.9% |
| 1-Year ReturnPast 12 months | +288.8% | +110.4% |
| 3-Year ReturnCumulative with dividends | -42.1% | +19.7% |
| 5-Year ReturnCumulative with dividends | -78.8% | -69.1% |
| 10-Year ReturnCumulative with dividends | -76.3% | -87.0% |
| CAGR (3Y)Annualised 3-year return | -16.7% | +6.2% |
Evenly matched — ACRS and DBVT each lead in 3 of 6 comparable metrics.
Risk & Volatility
ACRS leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
ACRS is the less volatile stock with a 0.30 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ACRS currently trades 99.4% from its 52-week high vs DBVT's 76.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ACRSAclaris Therapeut… | DBVTDBV Technologies … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.30x | 1.26x |
| 52-Week HighHighest price in past year | $4.89 | $26.18 |
| 52-Week LowLowest price in past year | $1.16 | $7.53 |
| % of 52W HighCurrent price vs 52-week peak | +99.4% | +76.3% |
| RSI (14)Momentum oscillator 0–100 | 66.0 | 48.1 |
| Avg Volume (50D)Average daily shares traded | 1.9M | 252K |
ACRS leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates ACRS as "Buy" and DBVT as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 105.8% for ACRS (target: $10).
| Metric | ACRSAclaris Therapeut… | DBVTDBV Technologies … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $10.00 | $46.33 |
| # AnalystsCovering analysts | 16 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ACRS leads in 2 of 6 categories (Profitability & Efficiency, Risk & Volatility). DBVT leads in 1 (Income & Cash Flow). 2 tied.
Best OverallAclaris Therapeutics, Inc. (ACRS)Leads 2 of 6 categories
Loading custom metrics...
ACRS vs DBVT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is ACRS or DBVT a better buy right now?
Analysts rate Aclaris Therapeutics, Inc.
(ACRS) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ACRS or DBVT?
Over the past 5 years, DBV Technologies S.
A. (DBVT) delivered a total return of -69. 1%, compared to -78. 8% for Aclaris Therapeutics, Inc. (ACRS). Over 10 years, the gap is even starker: ACRS returned -76. 3% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ACRS or DBVT?
By beta (market sensitivity over 5 years), Aclaris Therapeutics, Inc.
(ACRS) is the lower-risk stock at 0. 30β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 315% more volatile than ACRS relative to the S&P 500.
04Which is growing faster — ACRS or DBVT?
On earnings-per-share growth, the picture is similar: Aclaris Therapeutics, Inc.
grew EPS 69. 0% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ACRS or DBVT?
DBV Technologies S.
A. (DBVT) is the more profitable company, earning 0. 0% net margin versus -829. 6% for Aclaris Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DBVT leads at 0. 0% versus -975. 9% for ACRS. At the gross margin level — before operating expenses — ACRS leads at 73. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — ACRS or DBVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is ACRS or DBVT better for a retirement portfolio?
For long-horizon retirement investors, Aclaris Therapeutics, Inc.
(ACRS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 30)). Both have compounded well over 10 years (ACRS: -76. 3%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ACRS and DBVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.